50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#55

Triptorelin

Reproductive HealthTrelstarDecapeptylGonapeptylTriptorelin PamoateTriptorelin Acetate

A potent synthetic GnRH agonist used in the treatment of prostate cancer, endometriosis, uterine fibroids, and precocious puberty through sustained suppression of sex hormone production.

Share:

Overview

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with significantly enhanced potency and a longer duration of action compared to native GnRH. It was developed by modifying the sixth amino acid of the natural GnRH sequence (replacing glycine with D-tryptophan), which increases receptor binding affinity and resistance to enzymatic degradation. Triptorelin is approximately 100 times more potent than native GnRH.

Like other GnRH agonists, triptorelin works through a paradoxical mechanism. Initial administration causes a transient surge in LH and FSH release (the "flare" effect), followed by sustained downregulation and desensitization of pituitary GnRH receptors. This results in profound suppression of LH and FSH secretion and, consequently, a marked reduction in gonadal sex steroid production — testosterone in males and estradiol in females — to castrate or postmenopausal levels within 2-4 weeks.

Triptorelin is widely used in oncology for the treatment of hormone-sensitive prostate cancer, where testosterone suppression is a cornerstone of therapy. It is also used in gynecology for the treatment of endometriosis, uterine fibroids, and as part of assisted reproductive technology protocols. In pediatric endocrinology, triptorelin is a standard treatment for central precocious puberty, where it effectively halts premature sexual development by suppressing the premature activation of the hypothalamic-pituitary-gonadal axis.

Extended-release formulations of triptorelin allow for monthly, 3-monthly, or 6-monthly depot injections, improving patient compliance and ensuring consistent hormone suppression. The drug has a well-established safety profile based on decades of clinical use across multiple therapeutic areas.

Research Uses & Applications

  • Treatment of advanced prostate cancer through testosterone suppression
  • Management of endometriosis symptoms and lesion regression
  • Preoperative treatment of uterine fibroids to reduce size before surgery
  • Treatment of central precocious puberty in children
  • Controlled ovarian stimulation protocols in assisted reproduction
  • Chemical castration in certain legal and clinical contexts

Key Research Findings

  • Large clinical trials demonstrated triptorelin reduces testosterone to castrate levels (<50 ng/dL) in over 95% of prostate cancer patients within 4 weeks.
  • Studies in endometriosis showed significant pain reduction and lesion regression comparable to other GnRH agonists after 6 months of treatment.
  • Long-term follow-up in children with central precocious puberty confirmed triptorelin effectively suppresses pubertal progression and preserves adult height potential.
  • Research comparing triptorelin depot formulations showed equivalent efficacy and safety between 1-month and 3-month formulations.
  • Studies demonstrated that triptorelin use prior to IVF can prevent premature LH surges and improve oocyte retrieval outcomes.

Risks & Side Effects

  • Initial testosterone flare can cause temporary worsening of prostate cancer symptoms including bone pain and urinary obstruction.
  • Hot flashes, decreased libido, and sexual dysfunction are common with sustained sex hormone suppression.
  • Long-term use associated with decreased bone mineral density and increased fracture risk.
  • Cardiovascular risk including potential increase in cardiac events with prolonged androgen deprivation.
  • Injection site reactions with depot formulations; mood changes and depression reported.

Administration

Administered as intramuscular or subcutaneous depot injection. Available as 1-month (3.75 mg), 3-month (11.25 mg), and 6-month (22.5 mg) depot formulations. For prostate cancer, treatment typically continues indefinitely or until disease progression. For endometriosis and fibroids, treatment is usually limited to 6 months. Add-back therapy with low-dose estrogen/progestin may be used to mitigate bone loss and vasomotor symptoms.

Legal Status

FDA-approved prescription medication (marketed as Trelstar in the US). Approved in Europe as Decapeptyl and Gonapeptyl. Available by prescription only. Classified as a prescription hormone therapy. Not a controlled substance.

Frequently Asked Questions

What is Triptorelin?

A potent synthetic GnRH agonist used in the treatment of prostate cancer, endometriosis, uterine fibroids, and precocious puberty through sustained suppression of sex hormone production.

What are the main uses of Triptorelin?

The primary research applications of Triptorelin include: Treatment of advanced prostate cancer through testosterone suppression; Management of endometriosis symptoms and lesion regression; Preoperative treatment of uterine fibroids to reduce size before surgery; Treatment of central precocious puberty in children; Controlled ovarian stimulation protocols in assisted reproduction; Chemical castration in certain legal and clinical contexts.

What are the risks and side effects of Triptorelin?

Documented risks and side effects include: Initial testosterone flare can cause temporary worsening of prostate cancer symptoms including bone pain and urinary obstruction.; Hot flashes, decreased libido, and sexual dysfunction are common with sustained sex hormone suppression.; Long-term use associated with decreased bone mineral density and increased fracture risk.; Cardiovascular risk including potential increase in cardiac events with prolonged androgen deprivation.; Injection site reactions with depot formulations; mood changes and depression reported.. Always consult a healthcare professional before considering any peptide.

Is Triptorelin legal?

FDA-approved prescription medication (marketed as Trelstar in the US). Approved in Europe as Decapeptyl and Gonapeptyl. Available by prescription only. Classified as a prescription hormone therapy. Not a controlled substance.

How is Triptorelin administered?

Administered as intramuscular or subcutaneous depot injection. Available as 1-month (3.75 mg), 3-month (11.25 mg), and 6-month (22.5 mg) depot formulations. For prostate cancer, treatment typically continues indefinitely or until disease progression. For endometriosis and fibroids, treatment is usually limited to 6 months. Add-back therapy with low-dose estrogen/progestin may be used to mitigate bone loss and vasomotor symptoms.

Related Peptides

#23

Kisspeptin-10

Reproductive Health

#28

Oxytocin

Reproductive Health

#54

Gonadorelin

Reproductive Health

#57

Alarelin

Reproductive Health

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #54 Gonadorelin#56 Bremelanotide →